Albireo Pharma Inc Kurs/ Buchwert
Was ist das Kurs/ Buchwert von Albireo Pharma Inc?
Kurs/ Buchwert von Albireo Pharma Inc ist 2.80
Was ist die Definition von Kurs/ Buchwert?
Kurs-Buchwert-Verhältnis repräsentiert das Verhältnis zwischen dem Aktienwert eines Unternehmens und dem Buchwert pro Aktie.
The price to book ratio, or P/B ratio, is a financial ratio used to compare a company's current market price to its book value. It is also sometimes known as a market to book ratio or price to equity ratio. The calculation of a price to book ratio can be performed in two ways. It can be calculated as the company's market capitalization divided by the company's total book value from its balance sheet. It can also be calculated using per-share values and dividing a company's current share price by the book value per share (i.e. its book value divided by the number of outstanding shares).
The P/B ratio varies between industries. The industries that require more infrastructure capital (for each dollar of profit) will usually trade at P/B ratios much lower than, for example, consulting firms. P/B ratios are commonly used to compare banks, because most assets and liabilities of banks are constantly valued at market values. A higher P/B ratio implies that investors expect management to create more value from a given set of assets, all else equal (and/or that the market value of the firm's assets is significantly higher than their accounting value).
P/B ratios do not, however, directly provide any information on the ability of the firm to generate profits or cash for shareholders. This ratio also gives some idea of whether an investor is paying too much for what would be left if the company went bankrupt immediately. For companies in distress, the book value is usually calculated without the intangible assets that would have no resale value. In such cases, P/B should also be calculated on a "diluted" basis, because stock options may well vest on sale of the company or change of control or firing of management.
Kurs/ Buchwert von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Albireo Pharma Inc
Was macht Albireo Pharma Inc?
Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. Albireo's lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases with Phase 3 pivotal trials in PFIC, Alagille syndrome and biliary atresia. The Company completed IND-enabling studies for new preclinical candidate A3907 this year and plans to advance development in adult liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year.
Unternehmen mit kurs/ buchwert ähnlich Albireo Pharma Inc
- Palo Alto Networks hat Kurs/ Buchwert von 2.80
- Dhanvarsha Finvest hat Kurs/ Buchwert von 2.80
- Saul Centers hat Kurs/ Buchwert von 2.80
- Tiziana Life Sciences Plc hat Kurs/ Buchwert von 2.80
- Gunpoint Exploration hat Kurs/ Buchwert von 2.80
- 2U Inc hat Kurs/ Buchwert von 2.80
- Albireo Pharma Inc hat Kurs/ Buchwert von 2.80
- Selan Exploration Technology hat Kurs/ Buchwert von 2.80
- Resilux NV hat Kurs/ Buchwert von 2.80
- Nasdaq Inc hat Kurs/ Buchwert von 2.80
- TransUnion hat Kurs/ Buchwert von 2.80
- Northern Shield Resources hat Kurs/ Buchwert von 2.80
- Parag Milk Foods hat Kurs/ Buchwert von 2.80